How much does Mounjaro cost per month in Spain: the real price per dose in 2026

When someone looks up how much Mounjaro costs per month, they usually find the price of one box and do the quick sum: one box equals one month. The problem is that the sum does not add up. Mounjaro (tirzepatide) is given once a week and each box contains four doses, which means it covers four weeks, not a calendar month. There are 52 weeks in a year, so you need 13 boxes rather than 12. On top of that, the first doses are lower and cheaper, and the medicine is not funded by the public health system, so 100% of the cost comes out of the patient's pocket. Let's break down the sum using the figures that have actually been verified.

What Mounjaro is and what you actually buy at the pharmacy

Mounjaro is the brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist, authorised in the European Union. It is given subcutaneously once a week using a pre-filled pen or a multi-dose KwikPen containing four doses. That is the unit you buy at the pharmacy: one box equals four weeks of treatment. It has been available in Spanish pharmacies since July 2024.

The Spanish product information lists two indications: as an adjunct to weight management diets and for type 2 diabetes. If you want to understand how the mechanism works before looking at prices, we have a detailed explanation of what GLP-1 drugs are and why they have changed the treatment of obesity, and a clinical comparison of Mounjaro versus Ozempic for anyone weighing up the two with their doctor.

The price per box, dose by dose

The indicative retail prices reported by OCU, ZAVA España, Holvia and Clínica UCOM for the four-dose box are as follows: 2.5 mg, €207.91; 5 mg, €271.35; 7.5 mg and 10 mg, €358.71; 12.5 mg and 15 mg, €446.07. Note one detail that saves unpleasant surprises: prices go by bands, not by milligram. The 7.5 mg box costs the same as the 10 mg box, and the 12.5 mg box the same as the 15 mg one. In other words, moving from 7.5 to 10 mg, or from 12.5 to 15 mg, does not push up the bill.

The word indicative needs to be taken seriously here. As it is not publicly funded, this is a medicine whose price is not set by the public funding system, and it can vary from one pharmacy to another, as Merca2 points out. The figures above give you a sense of the order of magnitude and let you compare doses with each other; they are not a guarantee of what your pharmacy receipt will say.

The monthly mistake: why 12 boxes a year are not enough

Here is the point almost nobody mentions. A weekly treatment needs 52 doses a year. Since each box holds four, that comes to 13 boxes a year, not 12. That mismatch means the real averaged monthly cost is roughly 8% higher than the price of one box. This is not a minor accounting quibble: on a treatment costing several thousand euros a year, that 8% is real money.

Spreading the 13 boxes across the 12 months of the year, the real monthly cost works out like this: on 5 mg, €293.96 a month, which comes to €3,527.55 a year; on 10 mg, €388.60 a month and €4,663.23 a year; on 15 mg, €483.24 a month and €5,798.91 a year. Those are the figures worth keeping in mind when planning a budget, not the standalone retail price of a box.

The first year costs less (and why)

In the first year you do not pay for the high dose from day one, because treatment starts in steps to improve digestive tolerance. Counting four weeks per step and 13 boxes in total, the first year up to 10 mg comes to €4,425.07, around €368.76 a month on average. If escalation goes as far as 15 mg, the first year comes to €5,211.31, around €434.28 a month.

It is important to understand what that means: the first year is cheaper than the years that follow at the same maintenance dose, not more expensive. The arithmetic is simple: you spend several months paying for boxes at the lower bands. And one caveat that is clinical rather than financial: we do not set out the exact dose escalation schedule or the maximum dose here, because that is laid down in the product information and decided by the doctor assessing you, case by case. If what worries you is the digestive side of that escalation, we go through it in our guide to the side effects of Ozempic and Mounjaro and how they are managed.

Is it covered by the Spanish public health system?

No. Mounjaro is marketed in Spain as a prescription-only medicine but is not funded by the Spanish National Health System, so the patient pays 100% of the cost. And this is not an exception specific to this drug: in Spain, GLP-1 drugs are not funded for their weight loss indication, as OCU reports, so whoever takes the treatment pays for all of it. It is worth knowing this before starting, because it is a sustained expense over time, not a one-off purchase.

That fact has a practical consequence: the price of the drug is only part of the budget. The initial medical assessment, blood tests where appropriate and follow-up all count too. We break down the whole picture in our guide to how much a medical weight loss treatment costs in Spain. And if what you want is to be sure that the route of purchase is legal and the product genuine, we explain that in how to obtain Ozempic and Mounjaro legally and safely in Spain.

What that money buys: what the trials measured

The price only makes sense alongside the measured efficacy. In SURMOUNT-1, a trial in people with obesity or overweight without diabetes followed for 72 weeks and published in NEJM in 2022, mean weight loss was 16.0% on 5 mg, 21.4% on 10 mg and 22.5% on 15 mg, compared with 2.4% on placebo (efficacy estimand). Using the more conservative treatment-regimen analysis, the figures were 19.5% on 10 mg and 20.9% on 15 mg.

Two essential caveats. First: these are averages from a clinical trial, with supervised diet and physical activity, not an individual guarantee; some people respond more and some less. Second, and this explains why the higher dose costs more: going from 5 to 15 mg does not double the result, it improves it by a few percentage points. The right dose is not the highest one, but the one that balances response and tolerability for each person, and that is for a doctor to determine.

On the long term, three-year SURMOUNT-1 data at week 176 were presented at the 2025 European Congress on Obesity held in Málaga: on 5 mg, 73% of participants had regained less than 5% from their lowest weight, 19% had regained between 5 and 10% and 8% had regained 10% or more; on the next dose up, the figures were 65%, 26% and 9%. This is a conference presentation, not a peer-reviewed paper, and should be read with that caution in mind. Even so, it points to something relevant for anyone doing the maths: keeping weight off is a long-distance race, a subject we develop in our article on why weight comes back after stopping treatment.

Comparing prices between drugs: be careful what you compare

When comparing costs it pays to look at how often each drug is given, because it completely changes the arithmetic. Saxenda (liraglutide), for example, is a GLP-1 analogue given daily, as opposed to the weekly administration of tirzepatide. Comparing the price of one pack with another without checking how many days of treatment each one covers leads to the wrong conclusions. The honest unit of comparison is the cost per week of treatment, or better still, per year.

In summary

What you need to take away is simple: the price of the box is not the price of the month, a year means 13 boxes, and in Spain this treatment is paid for in full because it is not publicly funded. Getting that sum right before you start avoids dropping out halfway through, which is the worst possible investment. What does exist today in Spain is medical weight loss treatment with a prior assessment, a prescription where appropriate from a registered doctor and ongoing follow-up, which is where it is decided whether it makes sense in your case and at what pace. With AiON you can check whether you are eligible in a few minutes and take the first step with the figures clear.